Potential use of nanocarriers with pentacyclic triterpenes in cancer treatments

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Jäger S, Trojan H, Kopp T, Laszczyk MN, Scheffler A. Pentacyclic triterpene distribution in various plants – rich sources for a new group of multi-potent plant extracts. Molecules 14(6), 2016–2031 (2009).
  MedlineGoogle Scholar
• 2 Zhang W, Men X, Lei P. Review on anti-tumor effect of triterpene acid compounds. J. Cancer Res. Ther. 10(5), 14 (2014).
  MedlineGoogle Scholar
• 3 Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 75(15), 1549–1560 (2009). • Summarizes the potential of triterpenes belonging to the lupane, oleanane or ursane group, to treat cancer by different modes of action.
  Medline CASGoogle Scholar
• 4 Chudzik M, Korzonek-Szlacheta I, Król W. Triterpenes as potentially cytotoxic compounds. Molecules 20(1), 1610–1625 (2015).
  MedlineGoogle Scholar
• 5 Jeong DW, Kim YH, Kim HH et al. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats. Biopharm. Drug Dispos. 28(2), 51–57 (2007).
  Medline CASGoogle Scholar
• 6 Jäger S, Laszczyk MN, Scheffler A. A preliminary pharmacokinetic study of betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba cortex). Molecules 13(12), 3224–3235 (2008).
  MedlineGoogle Scholar
• 7 Yin M-C, Lin M-C, Mong M-C, Lin C-Y. Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice. J. Agric. Food Chem. 60(31), 7697–7701 (2012).
  Medline CASGoogle Scholar
• 8 Xie J, Yang ZG, Zhou CG, Zhu J, Lee RJ, Teng LS. Nanotechnology for the delivery of phytochemicals in cancer therapy. Biotechnol. Adv. 34(4), 343–353 (2016).
  Medline CASGoogle Scholar
• 9 Li Z, Jiang H, Xu CM, Gu LW. A review: using nanoparticles to enhance absorption and bioavailability of phenolic phytochemicals. Food Hydrocolloid 43, 153–164 (2015).
  CASGoogle Scholar
• 10 Gunther G, Berrios E, Pizarro N et al. Flavonoids in microheterogeneous media, relationship between their relative location and their reactivity towards singlet oxygen. PLoS ONE 10(6), e0129749 (2015).
  MedlineGoogle Scholar
• 11 Pisha E, Chai H, Lee I-S et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med. 1(10), 1046–1051 (1995). • First report of triterpens as a inhibitor of human melanoma.
  Medline CASGoogle Scholar
• 12 Lúcio KA, Rocha Gda G, Monção-Ribeiro LC, Fernandes J, Takiya CM, Gattass CR. Oleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivo. PLoS ONE 6(12), e28596 (2011).
  Medline CASGoogle Scholar
• 13 Allouche Y, Warleta F, Campos MA et al. Antioxidant, antiproliferative, and pro-apoptotic capacities of pentacyclic triterpenes found in the skin of olives on MCF-7 human breast cancer cells and their effects on DNA damage. J. Agric. Food Chem. 59(1), 121–130 (2010).
  MedlineGoogle Scholar
• 14 George VC, Kumar DRN, Suresh PK, Kumar RA. Oleanolic acid inhibits cell growth and induces apoptosis in A375 melanoma cells. Biomed. Prev. Nutr. 4(2), 95–99 (2014).
  Google Scholar
• 15 Wei J, Liu H, Liu M et al. Oleanolic acid potentiates the antitumor activity of 5-fluorouracil in pancreatic cancer cells. Oncol. Rep. 28(4), 1339–1345 (2012).
  Medline CASGoogle Scholar
• 16 Villar VH, Vögler O, Barceló F et al. Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein. J. Nutr. Biochem. 25(4), 429–438 (2014).
  Medline CASGoogle Scholar
• 17 Yan S-L, Huang C-Y, Wu S-T, Yin M-C. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol. In Vitro 24(3), 842–848 (2010).
  Medline CASGoogle Scholar
• 18 Chakravarti B, Maurya R, Siddiqui JA et al. In vitro anti-breast cancer activity of ethanolic extract of Wrightia tomentosa: role of pro-apoptotic effects of oleanolic acid and urosolic acid. J. Ethnopharmacol. 142(1), 72–79 (2012).
  Medline CASGoogle Scholar
• 19 Wang X, Zhang F, Yang L et al. Ursolic acid inhibits proliferation and induces apoptosis of cancer cells in vitro and in vivo. BioMed Res. Int. 2011, 419343 (2011).
  Google Scholar
• 20 Wang J, Liu L, Qiu H et al. Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells. PLoS ONE 8(5), e63872 (2013).
  Medline CASGoogle Scholar
• 21 Weng H, Tan Z-J, Hu Y-P et al. Ursolic acid induces cell cycle arrest and apoptosis of gallbladder carcinoma cells. Cancer Cell Int. 14(96), 1–10 (2014).
  MedlineGoogle Scholar
• 22 Nam H, Kim M-M. Ursolic acid induces apoptosis of SW480 cells via p53 activation. Food Chem. Toxicol. 62, 579–583 (2013).
  Medline CASGoogle Scholar
• 23 Lin D, Zhang R, Feng T, Chen LI, Ying-Ying X, Tao X. Ursolic acid induces U937 cells differentiation by PI3K/Akt pathway activation. Chin. J. Nat. Med. 12(1), 15–19 (2014).
  MedlineGoogle Scholar
• 24 Park J-H, Kwon H-Y, Sohn EJ et al. Inhibition of Wnt/β-catenin signaling mediates ursolic acid-induced apoptosis in PC-3 prostate cancer cells. Pharmacol. Rep. 65(5), 1366–1374 (2013).
  Medline CASGoogle Scholar
• 25 Gao N, Cheng S, Budhraja A et al. Ursolic acid induces apoptosis in human leukaemia cells and exhibits anti-leukaemic activity in nude mice through the PKB pathway. Br. J. Pharmacol. 165(6), 1813–1826 (2012).
  Medline CASGoogle Scholar
• 26 Kim KH, Seo HS, Choi HS, Choi I, Shin YC, Ko S-G. Induction of apoptotic cell death by ursolic acid through mitochondrial death pathway and extrinsic death receptor pathway in MDA-MB-231 cells. Arch. Pharmacal Res. 34(8), 1363–1372 (2011).
  Medline CASGoogle Scholar
• 27 Shin SW, Park J-W. Ursolic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Biochim. Biophys. Acta 1833(3), 723–730 (2013).
  Medline CASGoogle Scholar
• 28 Zheng Q-Y, Li P-P, Jin F-S et al. Ursolic acid induces ER stress response to activate ASK1–JNK signaling and induce apoptosis in human bladder cancer T24 cells. Cell Signal. 25(1), 206–213 (2013).
  Medline CASGoogle Scholar
• 29 Zheng Q-Y, Jin F-S, Yao C, Zhang T, Zhang G-H, Ai X. Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem. Biophys. Res. Commun. 419(4), 741–747 (2012).
  Medline CASGoogle Scholar
• 30 Xavier CPR, Lima CF, Pedro DFN, Wilson JM, Kristiansen K, Pereira-Wilson C. Ursolic acid induces cell death and modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells. J. Nutr. Biochem. 24(4), 706–712 (2013).
  Medline CASGoogle Scholar
• 31 Limami Y, Pinon A, Leger DY et al. The P2Y 2/Src/p38/COX-2 pathway is involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer cells. Biochimie 94(8), 1754–1763 (2012).
  Medline CASGoogle Scholar
• 32 Shin SW, Kim SY, Park J-W. Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells. Biochim. Biophys. Acta 1823(2), 451–457 (2012).
  Medline CASGoogle Scholar
• 33 Huang C-Y, Lin C-Y, Tsai C-W, Yin M-C. Inhibition of cell proliferation, invasion and migration by ursolic acid in human lung cancer cell lines. Toxicol. In Vitro 25(7), 1274–1280 (2011).
  Medline CASGoogle Scholar
• 34 Limami Y, Pinon A, Leger DY et al. HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death. Biochimie 93(4), 749–757 (2011).
  Medline CASGoogle Scholar
• 35 Messner B, Zeller I, Ploner C et al. Ursolic acid causes DNA-damage, p53-mediated, mitochondria-and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis 219(2), 402–408 (2011).
  Medline CASGoogle Scholar
• 36 Foo JB, Yazan LS, Tor YS et al. Induction of cell cycle arrest and apoptosis by betulinic acid-rich fraction from Dillenia suffruticosa root in MCF-7 cells involved p53/p21 and mitochondrial signalling pathway. J. Ethnopharmacol. 166, 270–278 (2015).
  Medline CASGoogle Scholar
• 37 Dash SK, Chattopadhyay S, Tripathy S et al. Self-assembled betulinic acid augments immunomodulatory activity associates with IgG response. Biomed. Pharmacother. 75, 205–217 (2015).
  Medline CASGoogle Scholar
• 38 Potze L, Mullauer FB, Colak S, Kessler JH, Medema JP. Betulinic acid-induced mitochondria-dependent cell death is counterbalanced by an autophagic salvage response. Cell Death Dis. 5, e1169 (2014).
  Medline CASGoogle Scholar
• 39 Yang J, Qiu B, Li X, Zhang H, Liu W. p53-p66 shc/miR-21-Sod2 signaling is critical for the inhibitory effect of betulinic acid on hepatocellular carcinoma. Toxicol. Lett. 238(3), 1–10 (2015).
  Medline CASGoogle Scholar
• 40 Martins WK, Costa ÉT, Cruz MC et al. Parallel damage in mitochondrial and lysosomal compartments promotes efficient cell death with autophagy: The case of the pentacyclic triterpenoids. Sci. Rep. 5, 12425 (2015).
  MedlineGoogle Scholar
• 41 Jung J. Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol. Res. 30(1), 1–5 (2014).
  MedlineGoogle Scholar
• 42 Saraswati S, Agrawal SS, Alhaider AA. Ursolic acid inhibits tumor angiogenesis and induces apoptosis through mitochondrial-dependent pathway in Ehrlich ascites carcinoma tumor. Chem. Biol. Interact. 206(2), 153–165 (2013).
  Medline CASGoogle Scholar
• 43 Wang X, Bai H, Zhang X et al. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK–p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis. Carcinogenesis 34(6), 1323–1330 (2013).
  Medline CASGoogle Scholar
• 44 Li L, Wei LH, Shen A, Chu JF, Lin JM, Peng J. Oleanolic acid modulates multiple intracellular targets to inhibit colorectal cancer growth. Int. J. Oncol. 47(6), 2247–2254 (2015).
  Medline CASGoogle Scholar
• 45 Gao Y, Jia ZL, Kong XY et al. Combining betulinic acid and mithramycin A effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res. 71(15), 5182–5193 (2011).
  Medline CASGoogle Scholar
• 46 Hsu TI, Wang MC, Chen SY et al. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of Sp1 to inhibit lung cancer growth. Mol. Pharmacol. 82(6), 1115–1128 (2012).
  Medline CASGoogle Scholar
• 47 Hsu TI, Chen YJ, Hung CY et al. A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy. Oncotarget 6(15), 13671–13687 (2015).
  MedlineGoogle Scholar
• 48 Mertens-Talcott SU, Noratto GD, Li XR, Angel-Morales G, Bertoldi MC, Safe S. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and MicroRNA-27a:ZBTB10. Mol. Carcinog. 52(8), 591–602 (2013).
  Medline CASGoogle Scholar
• 49 Song M, Hang T-J, Wang Y et al. Determination of oleanolic acid in human plasma and study of its pharmacokinetics in Chinese healthy male volunteers by HPLC tandem mass spectrometry. J. Pharm. Biomed. Anal. 40(1), 190–196 (2006).
  Medline CASGoogle Scholar
• 50 Liao Q, Yang W, Jia Y, Chen X, Gao Q, Bi K. LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. Yakugaku Zasshi 125(6), 509–515 (2005).
  Medline CASGoogle Scholar
• 51 Cheng X, Shin YG, Levine BS, Smith AC, Tomaszewski JE, Van Breemen RB. Quantitative analysis of betulinic acid in mouse, rat and dog plasma using electrospray liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 17(18), 2089–2092 (2003).
  Medline CASGoogle Scholar
• 52 Chen Q, Luo S, Zhang Y, Chen Z. Development of a liquid chromatography–mass spectrometry method for the determination of ursolic acid in rat plasma and tissue: application to the pharmacokinetic and tissue distribution study. Anal. Bioanal. Chem. 399(8), 2877–2884 (2011).
  Medline CASGoogle Scholar
• 53 Hirsh S, Huber L, Zhang P, Stein R, Joyal S. A single ascending dose, initial clinical pharmacokinetic and safety study of ursolic acid in healthy adult volunteers. FASEB J. 28(Suppl. 1), 1044 (2014).
  MedlineGoogle Scholar
• 54 Udeani GO, Zhao GM, Geun Shin Y et al. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice1. Biopharm. Drug Disposition 20(8), 379–383 (1999).
  Medline CASGoogle Scholar
• 55 Subramanyam R, Gollapudi A, Bonigala P, Chinnaboina M, Amooru DG. Betulinic acid binding to human serum albumin: a study of protein conformation and binding affinity. J. Photochem. Photobiol. B 294(1), 8–12 (2009).
  Google Scholar
• 56 Shetty P, Mangaonkar K, Sane R, Jaripatke K, Singh S. Pharmacokinetic analysis of ursolic acid in Alstonia scholaris R. Br. by high-performance thin-layer chromatography. JPC J. Planar Chromatogr. Modern TLC 20(2), 117–120 (2007).
  CASGoogle Scholar
• 57 Ji HY, Shin BS, Jeong DW et al. Interspecies scaling of oleanolic acid in mice, rats, rabbits and dogs and prediction of human pharmacokinetics. Arch. Pharm. Res. 32(2), 251–257 (2009).
  Medline CASGoogle Scholar
• 58 Chen RJ, Liu X, Li PM, Zhang L, Zhao L, Zhang XL. Pharmacokinetic profiles of oleanolic acid formulations in healthy Chinese male volunteers. Chin. Pharm. J. 45, 621–626 (2010).
  CASGoogle Scholar
• 59 Rada M, Castellano JM, Perona JS, Guinda Á. GC-FID determination and pharmacokinetic studies of oleanolic acid in human serum. Biomed. Chromatogr. 29(11), 1687–1692 (2015).
  Medline CASGoogle Scholar
• 60 Du H, Chen X. CD-MEKC method to analyze triterpene acids in traditional Chinese medicines. J. Braz. Chem. Soc. 20(7), 1268–1274 (2009).
  CASGoogle Scholar
• 61 Shanmugam MK, Dai X, Kumar AP, Tan BKH, Sethi G, Bishayee A. Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem. Pharmacol. 85(11), 1579–1587 (2013).
  Medline CASGoogle Scholar
• 62 Xi J, Chang Q, Chan CK et al. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS PharmSciTech 10(1), 172–182 (2009).
  Medline CASGoogle Scholar
• 63 Qiang Z, Ye Z, Hauck C et al. Permeability of rosmarinic acid in Prunella vulgaris and ursolic acid in Salvia officinalis extracts across Caco-2 cell monolayers. J. Ethnopharmacol. 137(3), 1107–1112 (2011).
  Medline CASGoogle Scholar
• 64 Aqil F, Munagala R, Jeyabalan J, Vadhanam MV. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 334(1), 133–141 (2013).
  Medline CASGoogle Scholar
• 65 Valdes K, Morilla MJ, Romero E, Chavez J. Physicochemical characterization and cytotoxic studies of nonionic surfactant vesicles using sucrose esters as oral delivery systems. Colloid Surf. B 117, 1–6 (2014).
  Medline CASGoogle Scholar
• 66 Morales JO, Valdes K, Morales J, Oyarzun-Ampuero F. Lipid nanoparticles for the topical delivery of retinoids and derivatives. Nanomedicine 10(2), 253–269 (2015).
  CASGoogle Scholar
• 67 Chuan LI, Zhang J, Yu-Jiao ZU et al. Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals. Chin. J. Nat. Med. 13(9), 641–652 (2015).
  MedlineGoogle Scholar
• 68 Gao Y, Xie J, Chen H et al. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotechnol. Adv. 32(4), 761–777 (2014). •• Examines nanotechnology and strategies for intelligent design of new nanomedicines for cancer metastasis treatment.
  Medline CASGoogle Scholar
• 69 Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Del. Rev. 66, 2–25 (2014).
  Medline CASGoogle Scholar
• 70 Amiji MM. Nanotechnology for Cancer Therapy. CRC Press, USA (2006).
  Google Scholar
• 71 Cancer Nanotechnology, Methods and Protocols. Grobmyer SR, Moudgil BM (Eds). Springer (2010).
  Google Scholar
• 72 Wang S, Su R, Nie S et al. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem. 25(4), 363–376 (2014).
  Medline CASGoogle Scholar
• 73 Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem. Rev. 115(19), 10938–10966 (2015).
  Medline CASGoogle Scholar
• 74 Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv. Colloid Interface Sci. 58(1), 1–55 (1995).
  CASGoogle Scholar
• 75 Sandoval C, Ortega A, Sanchez SA, Morales J, Gunther G. Structuration in the interface of direct and reversed micelles of sucrose esters, studied by fluorescent techniques. PLoS ONE 10(4), e0123669 (2015).
  MedlineGoogle Scholar
• 76 Han SK, Ko YI, Park SJ, Jin IJ, Kim YM. Oleanolic acid and ursolic acid stabilize liposomal membranes. Lipids 32(7), 769–773 (1997).
  Medline CASGoogle Scholar
• 77 Both DM, Goodtzova K, Yarosh DB, Brown DA. Liposome-encapsulated ursolic acid increases ceramides and collagen in human skin cells. Arch. Dermatol. Res. 293(11), 569–575 (2002).
  Medline CASGoogle Scholar
• 78 Caldeira De Araújo Lopes S, Vinícius Melo Novais M, Salviano Teixeira C et al. Preparation, physicochemical characterization, and cell viability evaluation of long-circulating and pH-sensitive liposomes containing ursolic acid. BioMed. Res. Int. 2013, 467147 (2013).
  MedlineGoogle Scholar
• 79 Kang HS, Park J-E, Lee Y-J, Chang I-S, Chung Y-I, Tae G. Preparation of liposomes containing oleanolic acid via micelle-to-vesicle transition. J. Nanosci. Nanotechnol. 7(11), 3944–3948 (2007).
  Medline CASGoogle Scholar
• 80 Gao D, Tang S, Tong Q. Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery. Int. J. Nanomed. 7, 3517 (2012).
  Medline CASGoogle Scholar
• 81 Mullauer FB, Van Bloois L, Daalhuisen JB et al. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anti Cancer Drugs 22(3), 223–233 (2011). •• Interesting in vitro and in vivo results of PEGylated liposomes.
  Medline CASGoogle Scholar
• 82 Yang G, Yang T, Zhang W, Lu M, Ma X, Xiang G. In vitro and in vivo antitumor effects of folate-targeted ursolic acid stealth liposome. J. Agric. Food Chem. 62(10), 2207–2215 (2014). • Interesting in vitro and in vivo results of ursolic acid-liposomes.
  Medline CASGoogle Scholar
• 83 Liu YP, Gao DW, Zhang XW et al. Antitumor drug effect of betulinic acid mediated by polyethylene glycol modified liposomes. Mat. Sci. Eng. C Mater. Biol. App. 64, 124–132 (2016).
  Medline CASGoogle Scholar
• 84 Bian Y, Gao D, Liu Y et al. Preparation and study on anti-tumor effect of chitosan-coated oleanolic acid liposomes. RSC Adv. 5(24), 18725–18732 (2015).
  CASGoogle Scholar
• 85 Jamal M, Imam SS, Aqil M, Amir M, Mir SR, Mujeeb M. Transdermal potential and anti-arthritic efficacy of ursolic acid from niosomal gel systems. Int. Immunopharmacol. 29(2), 361–369 (2015).
  Medline CASGoogle Scholar
• 86 Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. J. Biomater. Nanobiotechnol. 2(05), 626 (2011).
  CASGoogle Scholar
• 87 Dehelean CA, Feflea S, Ganta S, Amiji M. Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. J. Biomed. Nanotechnol. 7(2), 317–324 (2011).
  Medline CASGoogle Scholar
• 88 Cavazos-Garduño A, Flores AaO, Serrano-Niño JC, Martínez-Sanchez CE, Beristain CI, García HS. Preparation of betulinic acid nanoemulsions stabilized by ω-3 enriched phosphatidylcholine. Ultrason. Sonochem. 24, 204–213 (2015).
  Medline CASGoogle Scholar
• 89 Alvarado HL, Abrego G, Souto EB et al. Nanoemulsions for dermal controlled release of oleanolic and ursolic acids: in vitro, ex vivo and in vivo characterization. Colloids Surf. B. Biointerfaces 130, 40–47 (2015).
  Medline CASGoogle Scholar
• 90 Zhou XJ, Hu XM, Yi YM, Wan J. Preparation and body distribution of freeze-dried powder of ursolic acid phospholipid nanoparticles. Drug Dev. Ind. Pharm. 35(3), 305–310 (2009).
  Medline CASGoogle Scholar
• 91 Sun Z, Ma CH, Yang L, Zu YG, Zhang RR. Production of ursolic acid nanoparticles by supercritical antisolvent precipitation. Adv. Mater. Res. 233–235, 2210–2214 (2011).
  CASGoogle Scholar
• 92 Zhang H, Li X, Ding J et al. Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int. J. Pharm. 441(1), 261–268 (2013).
  Medline CASGoogle Scholar
• 93 Mandelli AM, Nadia A, Denise CJ, Mary KT, Rolim BA, Robles VMV. Evaluation of physical and chemical stability of nanostructured lipid carries containing ursolic acid in cosmetic formulation. J. Appl. Pharm. Sci. 3(1), 5–8 (2013).
  Google Scholar
• 94 Kim S-M, Chae MK, Yim MS et al. Hybrid PET/MR imaging of tumors using an oleanolic acid-conjugated nanoparticle. Biomaterials 34(33), 8114–8121 (2013).
  Medline CASGoogle Scholar
• 95 Hussein-Al-Ali SH, Arulselvan P, Fakurazi S, Hussein MZ. The in vitro therapeutic activity of betulinic acid nanocomposite on breast cancer cells (MCF-7) and normal fibroblast cell (3T3). J. Mater. Sci. 49(23), 8171–8182 (2014).
  CASGoogle Scholar
• 96 Tan JM, Karthivashan G, Arulselvan P, Fakurazi S, Hussein MZ. Characterization and in vitro studies of the anticancer effect of oxidized carbon nanotubes functionalized with betulinic acid. Drug Des. Devel. Ther. 8, 2333 (2014).
  MedlineGoogle Scholar
• 97 Dai L, Cao X, Liu K-F et al. Self-assembled targeted folate-conjugated eight-arm-polyethylene glycol–betulinic acid nanoparticles for co-delivery of anticancer drugs. J. Mater. Chem. B 3(18), 3754–3766 (2015).
  Medline CASGoogle Scholar
• 98 Singh R, Bharti N, Madan J, Hiremath SN. Characterization of cyclodextrin inclusion complexes – a review. J. Pharm. Sci. Technol 2(3), 171–183 (2010).
  CASGoogle Scholar
• 99 Cerga O, Borcan F, Ambrus R, Popovici I. Syntheses of new cyclodextrin complexes with oleanolic and ursolic acids. J. Agroaliment. Process. Technol 17, 405–409 (2011).
  CASGoogle Scholar
• 100 Sun Y-F, Song C-K, Viernstein H, Unger F, Liang Z-S. Apoptosis of human breast cancer cells induced by microencapsulated betulinic acid from sour jujube fruits through the mitochondria transduction pathway. Food Chem. 138(2), 1998–2007 (2013).
  Medline CASGoogle Scholar
• 101 Soica C, Danciu C, Savoiu-Balint G et al. Betulinic acid in complex with a gamma-cyclodextrin derivative decreases proliferation and in vivo tumor development of non-metastatic and metastatic B164A5 cells. Int. J. Mol. Sci. 15(5), 8235–8255 (2014).
  Medline CASGoogle Scholar
• 102 Soica C, Oprean C, Borcan F et al. The synergistic biologic activity of oleanolic and ursolic acids in complex with hydroxypropyl-γ-cyclodextrin. Molecules 19(4), 4924–4940 (2014).
  Medline CASGoogle Scholar
• 103 Wang Y, Song J, Chow SF, Chow AHL, Zheng Y. Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation. Int. J. Pharm. 494(1), 479–489 (2015).
  Medline CASGoogle Scholar
• 104 Gao Y, Li Z, Xie X et al. Dendrimeric anticancer prodrugs for targeted delivery of ursolic acid to folate receptor-expressing cancer cells: synthesis and biological evaluation. Eur. J. Pharm. Sci. 70, 55–63 (2015).
  Medline CASGoogle Scholar
• 105 Li W, Das S, Ng K-Y, Heng PWS. Formulation, biological and pharmacokinetic studies of sucrose ester-stabilized nanosuspensions of oleanolic acid. Pharm. Res. 28(8), 2020–2033 (2011).
  Medline CASGoogle Scholar
• 106 Zhao T, Liu Y, Gao Z et al. Self-assembly and cytotoxicity study of PEG-modified ursolic acid liposomes. Mater. Sci. Eng. 53, 196–203 (2015).
  Medline CASGoogle Scholar
• 107 Wang X-H, Zhou S-Y, Qian Z-Z et al. Evaluation of toxicity and single-dose pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and patients with advanced solid tumors. Expert Opin. Drug Metab. Toxicol. 9(2), 117–125 (2013). •• First report of ursolic acid-nanocarriers in human.
  Medline CASGoogle Scholar
• 108 Zhu Z, Qian Z, Yan Z, Zhao C, Wang H, Ying G. A Phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors. Int. J. Nanomed. 8, 129 (2013).
  MedlineGoogle Scholar
• 109 Qian Z, Wang X, Song Z et al. A Phase I trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors. BioMed Res. Int. 2015, 809714 (2015).
  MedlineGoogle Scholar